Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity

Bioorganic & Medicinal Chemistry
2014.0

Abstract

Analogues of endomorphin (Dmt-Pro-Xaa-Xaa-NH2) modified at position 4 or at positions 4 and 3, and tripeptides (Dmt-Pro-Xaa-NH2) modified at position 3, with various phenylalanine analogues (Xaa=Trp, 1-Nal, 2-Nal, Tmp, Dmp, Dmt) were synthesized and their effects on in vitro opioid activity were investigated. Most of the peptides exhibited high μ-opioid (MOP) receptor binding affinity (KiMOP=0.13-0.81nM), modest MOP-selectivity (Kiδ-opioid (DOP)/KiMOP=3.5-316), and potent functional MOP agonism (GPI, IC50=0.274-249nM) without DOP and κ-opioid (KOP) receptor agonism. Among them, compounds 7 (Dmt-Pro-Tmp-Tmp-NH2) and 9 (Dmt-Pro-1-Nal-NH2) were opioids with potent mixed MOP receptor agonism/DOP receptor antagonism and devoid of β-arrestin2 recruitment activity. They may offer a unique template for the discovery of potent analgesics that produce less respiratory depression, less gastrointestinal dysfunction and that have a lower propensity to induce tolerance and dependence compared with morphine.

Knowledge Graph

Similar Paper

Endomorphin analogues with mixed μ-opioid (MOP) receptor agonism/δ-opioid (DOP) receptor antagonism and lacking β-arrestin2 recruitment activity
Bioorganic & Medicinal Chemistry 2014.0
Biological activity of endomorphin and [Dmt1]endomorphin analogs with six-membered proline surrogates in position 2
Bioorganic & Medicinal Chemistry 2009.0
Endomorphin-1 Analogues Containing β-Proline Are μ-Opioid Receptor Agonists and Display Enhanced Enzymatic Hydrolysis Resistance
Journal of Medicinal Chemistry 2002.0
Design, Synthesis, Pharmacological Evaluation, and Structure−Activity Study of Novel Endomorphin Analogues with Multiple Structural Modifications
Journal of Medicinal Chemistry 2011.0
Synthesis of Mixed Opioid Affinity Cyclic Endomorphin-2 Analogues with Fluorinated Phenylalanines
ACS Medicinal Chemistry Letters 2015.0
Novel highly potent μ-opioid receptor antagonist based on endomorphin-2 structure
Bioorganic & Medicinal Chemistry Letters 2008.0
Synthesis and Characterization of Potent and Selective μ-Opioid Receptor Antagonists, [Dmt, <scp>d</scp>-2-Nal<sup>4</sup>]endomorphin-1 (Antanal-1) and [Dmt<sup>1</sup>, <scp>d</scp>-2-Nal<sup>4</sup>]endomorphin-2 (Antanal-2)
Journal of Medicinal Chemistry 2007.0
Design, Synthesis, and Pharmacological Characterization of Novel Endomorphin-1 Analogues as Extremely Potent μ-Opioid Agonists
Journal of Medicinal Chemistry 2013.0
The Effect of Pro<sup>2</sup> Modifications on the Structural and Pharmacological Properties of Endomorphin-2
Journal of Medicinal Chemistry 2012.0
Synthesis and binding activity of endomorphin-1 analogues containing β-amino acids
Bioorganic &amp; Medicinal Chemistry Letters 2000.0